Breast cancer

**Early stage TNBC**
- Neoadjuvant
  - **10013**: Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, with or without Atezolizumab in Triple Negative Breast Cancer (TNBC)

**Locally advanced/metastatic TNBC**
- First line
  - **10020**: A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (Atezolizumab MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HR2-Positive Breast Cancer
  - **9876**: Phase 1b Study of HSP90 Inhibitor, AT13387 in Combination with Paclitaxel in Patients with Advanced, Triple Negative Breast Cancer
  - **10146**: Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab in Patients with Metastatic Triple Negative Breast Cancer

**Later line**
- First or second line
  - **10287**: A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination with Copanlisib (FAC) Versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA)
  - **10195**: A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination with Fulvestrant in Women with Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor

**ER+/HER2- breast cancer**
- Locally advanced/metastatic ER+/HER2-
  - First line
  - **10031**: A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors with Expansion in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (Currently in dose escalation)
  - **9844**: A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or Without Ipilimumab in Advanced Solid Tumors (In expansion cohort)

**TNBC or ER+/HER2- breast cancer**
- PTEN or PIK3CB mutation
  - Later line
    - **10131**: A Phase I Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel (Currently in dose escalation. Expansion cohorts include breast, prostate, and other solid tumors.)

**NOTE**: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: 10/11/2018